Skip to main content
< Back to news
The opening ceremony was conducted by Antoni Esteve, president of the FCRi.
 17.04.2015

A meeting point aimed at changing business perceptions of research in Biomed

More than 150 businesses, researchers and investors gathered yesterday at the  Foro Ciencia Empresa FCRi – Fundación EY, Open Innovation at Biomed, a conference organized by the Catalan Foundation of Research and Innovation (FCRi) and the Fundación EY at the Sant Pau Art Nouveau Site. Several projects of BEC and IRB Barcelona and business proposals from 'EnantiaIntelligent Pharma, Miru Medical Systems and Stat-Diagnostica –based at the  Parc Científic de Barcelona– were among the 22 Catalan business and biomedical research initiatives that were presented as business opportunities to companies and investors. Montserrat Vendrell, general director of PCB, actively participated at the conference as a speaker in the panel discussion.

 

The core of the Forum, which has been designed to increase the level of knowledge among business on the market projection of the main trends in biomedical research, was the brief presentation of 12 projects and business initiatives in biomedical research: six of these projects are in an advanced phase and a further 6 are emerging. They were selected by a committee of experts according to their scientific content profile and socioeconomic impact.

Presentations were five minutes log and were open to questions, which generated much debate in the vast majority of cases. Ten academic projects with potential to transfer to the market were  presented and explained by those responsible alongside the space called Entrepreneur meeting point.   A total of 40 one-to-one meetings were also held in a specific networking area at the end of the conference.

The meeting also hosted the roundtable “From research to market, science and business management in the BioMed sector”, moderated by Josep Lluís Sanfeliu, founder partner of Ysios Capital with the participation Montserrat Vendrell, general director of PCB (PCB ); Ignasi Biosca, president of CataloniaBio and CEO of Reig Jofre; and Irene Norstedt, executive director of Innovative Medicines Initiative (IMI).

The presentations were complemented by the participation of various speakers such as Anne Glover, president of the European Private Equity & Venture Capital Association (EVCA) and co-founder of Amadeus Capital Partners, and Silvia Ondategui-Parra, partner and  consultancy leaderfor the pharmaceutical and health sector of EY.

The event was inaugurated by Antoni Esteve, president of FCRi and Farmaindustria, and Eva Maria Abans, managing partner of the EY Office in Barcelona. The closing ceremony was conducted by Claudi Alsina, Secretary General of the Inter-University Council of Catalonia. The Forum was broadcasted entirely by videostreaming.

Business proposals and academic projects with market projection

Participating business in advanced phase included AB-Biotics SA; Intelligent Pharma SL; Oryzon Genomics SA; GP Pharm SA / BCN Peptides SA; Stat Diagnostica & Innovation SL and Enantia SL. Emerging cases (less than 5 years in operation) were presented by HIV-Therapeutics SL; Inbiomotion SL; Minoryx Therapeutics SL; Mosaic Biomedicals SL; Galgo Medical SL; and Miru Medical Systems SL.

The 10 academic projects integrated at the Entrepreneur meeting point corresponded to the research teams led by Eduard Batlle (IRB Barcelona), Manel Esteller (IDIBELL), Valerio Pruneri (ICFO), Modesto Orozco (IRB–BSC–UB), Francisco Lozano (IDIBAPS-HCB), Ángel Diéguez (UB), Antoni Ivorra (UPF), Mario Cáceres (UAB) and Pere-Joan Cardona (IGTP), in addition to an exhibition of Sincrotón ALBA.